U.S. markets open in 5 hours 27 minutes
  • S&P Futures

    3,840.75
    -7.75 (-0.20%)
     
  • Dow Futures

    30,836.00
    -32.00 (-0.10%)
     
  • Nasdaq Futures

    13,444.75
    -30.75 (-0.23%)
     
  • Russell 2000 Futures

    2,153.70
    -7.30 (-0.34%)
     
  • Crude Oil

    52.75
    -0.02 (-0.04%)
     
  • Gold

    1,854.00
    -1.20 (-0.06%)
     
  • Silver

    25.47
    -0.01 (-0.05%)
     
  • EUR/USD

    1.2137
    -0.0007 (-0.06%)
     
  • 10-Yr Bond

    1.0400
    0.0000 (0.00%)
     
  • Vix

    23.37
    +1.46 (+6.66%)
     
  • GBP/USD

    1.3644
    -0.0031 (-0.23%)
     
  • USD/JPY

    103.7990
    +0.0430 (+0.04%)
     
  • BTC-USD

    31,935.99
    -432.29 (-1.34%)
     
  • CMC Crypto 200

    645.72
    -31.17 (-4.61%)
     
  • FTSE 100

    6,676.01
    +37.16 (+0.56%)
     
  • Nikkei 225

    28,546.18
    -276.11 (-0.96%)
     

We Think Adial Pharmaceuticals (NASDAQ:ADIL) Needs To Drive Business Growth Carefully

Simply Wall St
·4 min read

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining exploration companies often lose money for years before finding success with a new treatment or mineral discovery. But while history lauds those rare successes, those that fail are often forgotten; who remembers Pets.com?

So, the natural question for Adial Pharmaceuticals (NASDAQ:ADIL) shareholders is whether they should be concerned by its rate of cash burn. In this report, we will consider the company's annual negative free cash flow, henceforth referring to it as the 'cash burn'. First, we'll determine its cash runway by comparing its cash burn with its cash reserves.

Check out our latest analysis for Adial Pharmaceuticals

When Might Adial Pharmaceuticals Run Out Of Money?

A company's cash runway is calculated by dividing its cash hoard by its cash burn. When Adial Pharmaceuticals last reported its balance sheet in September 2020, it had zero debt and cash worth US$7.4m. In the last year, its cash burn was US$6.8m. That means it had a cash runway of around 13 months as of September 2020. While that cash runway isn't too concerning, sensible holders would be peering into the distance, and considering what happens if the company runs out of cash. Depicted below, you can see how its cash holdings have changed over time.

debt-equity-history-analysis
debt-equity-history-analysis

How Is Adial Pharmaceuticals' Cash Burn Changing Over Time?

Adial Pharmaceuticals didn't record any revenue over the last year, indicating that it's an early stage company still developing its business. So while we can't look to sales to understand growth, we can look at how the cash burn is changing to understand how expenditure is trending over time. Over the last year its cash burn actually increased by 19%, which suggests that management are increasing investment in future growth, but not too quickly. That's not necessarily a bad thing, but investors should be mindful of the fact that will shorten the cash runway. While the past is always worth studying, it is the future that matters most of all. For that reason, it makes a lot of sense to take a look at our analyst forecasts for the company.

How Hard Would It Be For Adial Pharmaceuticals To Raise More Cash For Growth?

Given its cash burn trajectory, Adial Pharmaceuticals shareholders may wish to consider how easily it could raise more cash, despite its solid cash runway. Generally speaking, a listed business can raise new cash through issuing shares or taking on debt. One of the main advantages held by publicly listed companies is that they can sell shares to investors to raise cash and fund growth. By looking at a company's cash burn relative to its market capitalisation, we gain insight on how much shareholders would be diluted if the company needed to raise enough cash to cover another year's cash burn.

Since it has a market capitalisation of US$25m, Adial Pharmaceuticals' US$6.8m in cash burn equates to about 27% of its market value. That's fairly notable cash burn, so if the company had to sell shares to cover the cost of another year's operations, shareholders would suffer some costly dilution.

So, Should We Worry About Adial Pharmaceuticals' Cash Burn?

Even though its cash burn relative to its market cap makes us a little nervous, we are compelled to mention that we thought Adial Pharmaceuticals' cash runway was relatively promising. Looking at the factors mentioned in this short report, we do think that its cash burn is a bit risky, and it does make us slightly nervous about the stock. On another note, we conducted an in-depth investigation of the company, and identified 5 warning signs for Adial Pharmaceuticals (1 is a bit concerning!) that you should be aware of before investing here.

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of companies insiders are buying, and this list of stocks growth stocks (according to analyst forecasts)

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com.